Status:
COMPLETED
A Study of Nevirapine to Prevent HIV Transmission From Mothers to Their Babies
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Conditions:
HIV Infections
Pregnancy
Eligibility:
All Genders
13+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to see if giving the anti-HIV drug nevirapine (NVP) to HIV-positive pregnant women and their babies can help reduce the chance that a mother will give HIV to her baby duri...
Detailed Description
NVP has several properties that make it an attractive candidate for antiretroviral therapy to interrupt HIV-1 transmission in the intrapartum and early post-partum period. The pharmacokinetic profile ...
Eligibility Criteria
Inclusion Criteria
You may be eligible for this study if you:
- Are an HIV-positive pregnant woman.
- Have been pregnant for at least 28 weeks.
- Are at least 13 years of age (consent of parent or guardian is required if under 18).
Exclusion Criteria
You will not be eligible for this study if:
- Your baby will not live.
- You intend to breast-feed.
- You are allergic to benzodiazepines (a tranquilizer).
- You have a liver disorder.
- You have received non-nucleoside reverse transcriptase inhibitors (a class of anti-HIV drugs).
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
May 1 2001
Estimated Enrollment :
1244 Patients enrolled
Trial Details
Trial ID
NCT00000942
End Date
May 1 2001
Last Update
October 29 2021
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Hopital Hotel Dieu de Lyon
Lyon, France
2
CHRU de Nantes
Nantes, France
3
Universita Frederico II
Naples, Italy
4
Hosp Doce De Octubre
Madrid, Spain